Blau Farmaceutica releases 2025 sustainability report

• Blau Farmaceutica SA released its 2025 sustainability report, highlighting a push into locally made monoclonal antibodies, led by pembrolizumab.
• Cotia site secured an Anvisa Good Manufacturing Practices certificate for pembrolizumab active ingredient production, supporting a planned 2028 launch.
• Clinical development roadmap calls for a Phase I study starting in 2026, with trials expected in Europe or the US under EMA or FDA oversight.
• Industrial expansion plan targets four new production lines; two were completed in 2025, with start-up in 2026 pending regulatory clearance.
• Company cited a Global Zero Waste Gold certification, positioning circularity measures as a core environmental milestone for the sector.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Blau Farmaceutica SA published the original content used to generate this news brief on July 31, 2026, and is solely responsible for the information contained therein.